Despite recent publication of numerous putative biomarkers of prostate cancer we are still completely dependent clinically on serum PSA. There is still an urgent need for new markers and particularly those identifying significant cancers. This study evaluates a transcription factor secreted by prostate cancer as a simple ELISA test without the requirement for DRE. The sensitivity, specificity and stability of EN2 at room temperature would make this test attractive for diagnosis of prostate cancer and also potentially as a simple screening tool in the community. Results: EN2 was expressed and secreted by PC cell lines and PC tissue but not by normal prostate tissue or stroma. The presence of EN2 in urine was highly predictive of PC, with a sensitivity of 66% and a specificity of 88.2%, without requirement for DRE. There was no correlation with PSA levels.
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Statement of Translational Relevance
Despite recent publication of numerous putative biomarkers of prostate cancer we are still completely dependent clinically on serum PSA. There is still an urgent need for new markers and particularly those identifying significant cancers. This study evaluates a transcription factor secreted by prostate cancer as a simple ELISA test without the requirement for DRE. The sensitivity, specificity and stability of EN2 at room temperature would make this test attractive for diagnosis of prostate cancer and also potentially as a simple screening tool in the community.
Introduction
Prostate cancer (PC) is the second most common cause of cancer related death in men, with approximately 913,000 new cases world wide in 2008 (1).
Localised, organ-confined PC can be cured in a large proportion of patients by surgery or radiotherapy. Advanced and metastatic PC continues to be associated with a poor prognosis (2). Serum prostate specific antigen (PSA) has been used as a cancer marker for initial diagnosis, monitoring of response to treatment, prediction of PC risk and of treatment outcome. As a prostate-specific and not prostate cancer-specific marker, it lacks both sensitivity and specificity to accurately detect the presence of PC, requires adjustment for age and prostate volume, is frequently raised in non-cancer conditions such as benign hypertrophy and prostatitis and so far has been controversial as a screening tool (3-5). A conventional cut off level of 4ng/ml has predictive value for detection of the prostate cancer (6,7) but only 15% of cancers were detected at prostate biopsy in the Prostate Cancer Prevention Trial (PCPT) (8). Higher detection rates of up to 44% have been reported at this PSA level in other studies, but these, unlike PCPT, did not evaluate healthy asymptomatic men (8-10). Studies of men at different ages also suggests differential incidence of prostate cancer. For the third through eighth decades of life, the incidence of prostate cancer in the cohort of 1051 subjects studied by Sakr et al was 7%, 23%, 39%, 44%, and 65%, respectively (11) .
Lowering PSA cut off levels results in higher sensitivity at the expense of much lower specificity and true negative rates of 70-80% (8, 12, 13) . No refinement of PSA (e.g. free: total PSA ratio) or other biomarkers have reduced this true negative rate (13) .There is therefore an urgent need for new markers to overcome at least some of the limitations of serum PSA.
Biomarkers signifying the presence of any cancer may be defined on the basis of gene products uniquely expressed or overexpressed in tissue, serum or urine, in cancer compared to non-cancer. A number of genes are involved in early embryonic development and are subsequently re-expressed in cancer, for example the HOX genes, a family of homeodomain-containing transcription factors that determine the early identity of cells and tissues (14) .
We and others have shown that HOX gene dysregulation occurs in most common cancers, with evidence that targeting HOX/PBX binding has therapeutic value (15) (16) (17) (18) (19) . We have studied Engrailed-2 (En2), another member of this group which show a very high degree of functional conservation during development (20) . En2 is a transcriptional repressor, but is also has a role in translational regulation (20) . In addition to its developmental role, En2 has recently been shown to be a potential oncogene in breast cancer, as forcing its expression in the non-malignant mammary cells induces a malignant phenotype including increased cell proliferation and a loss of contact dependence (21) .
In this study we show that En2 is expressed in, and secreted by, prostate cancer but not normal prostatic tissue. The presence of EN2 protein in urine has been evaluated as a diagnostic biomarker for PC.
Materials and Methods
Patient and controls
This study was approved by the local research ethics committee (reference 09/H1109/84), and took place between June 2007 to June 2010. In total 194 urine samples were collected by the Surrey site. Men with lower urinary tract symptoms, individuals concerned they may have an asymptomatic PC (e.g. a positive family history) and men with an abnormal PSA test reading conducted by their family physician were referred into our specialist Uro-Oncology clinic.
The purpose of the referral was to exclude or confirm the presence of prostate cancer. Men with known PC on treatment, with any other known concurrent or previous cancers within 10 years or urinary tract infection (as determined by the presence of leukocytes using a dipstick test) were excluded. Urine samples from patients and controls were collected prospectively; samples were blinded to laboratory staff at the time of EN2 measurement.
Two control groups of men >40 years were also assessed: (a) 'low PSA group A'; men presenting to haematuria clinics where no urothelial malignancy was found (single episode of haematuria: radiology, cystoscopy and cytology negative) but in whom DRE and PSA (routinely performed in this clinic) were normal, PSA below 2·5 ng/ml. cDNA Synthesis RNA from prostate tumours and normal adjacent tissue was obtained from urology clinic patients. Prostate biopsy tissue was taken contiguous to a routine sextant biopsy (from which histology was later confirmed), placed in OCT (optimal cutting compound), snap frozen and stored in liquid nitrogen.
RNA was reverse transcribed as described previously (16) . confluence without a media change after seeding 10% confluence.
Statistical analysis
The Graphpad prism package was used in statistical calculations. In order to test the significance of differences between mean EN2 concentrations in different patient groups we used an unpaired t-test with Welch's correction.
Receiver operator characteristics (ROC) curves were generated for the EN2
and PSA values. The area under the curve was tested for significance using an unpaired t-test against the hypothesis that the real area under the curve was 0·5 (i.e. no diagnostic value).
Results
The complex regulatory functions and oncogenic potential (20) PC3, LNCaP and DU145 cell lines release EN2 protein into the surrounding medium, but not WPMY-1 (Fig 1c) , and immunofluorescent imaging of EN2 in PC3 cells revealed a high concentration of this protein close to the membrane consistent with its secretory potential (Fig 1d) .
These findings were supported by immunohistochemical study of PC and normal prostatic tissue using an anti-EN2 antibody stain in a large representative 195 core tissue array and in patient biopsies. In the tissue array EN2 was highly expressed in prostate cancer (92%, n=184 prostate cancer cores), but not in normal tissue adjacent to the tumour (0%, n=11), or in normal prostate cores (0%, n=9). We found no evidence of EN2 staining in normal prostate tissue, benign hypertrophy nor in men with HGPIN (high grade prostatic intra-epithelial neoplasia) in any tissue array section or biopsy from our patients. Analysis of larger tumour sections taken by biopsy revealed EN2 expression is most intense in the duct like structures of tumours (Fig 2a-c) , and that EN2 protein is present in the cytoplasm, and in some cases in the basal membrane, but not in the nucleus (Fig 2c) . Furthermore, blebs containing EN2 protein are apparent in prostatic acini and ducts (Fig 2b, c) .
This widespread distribution contrasts markedly with normal adult purkinje neurons where EN2 protein, as expected, is confined to the nucleus (27) (supplemental Fig 1) . We also compared the staining of EN2 to that of a known prostate cancer specific antigen, alpha-methylacyl-coenzyme A racemase (AMACR) (28); merged images of each staining pattern show an almost complete overlay (Fig 2d-f) .
Given the secretory properties of EN2 in embryonic development (29) and the observation of EN2-positive blebs within the lumen of malignant prostatic ducts, we looked for EN2 protein in the urine of men with biopsy-confirmed but untreated PC and controls. EN2 protein in untreated, unconcentrated urine from PC patients could be detected by western blotting with a band corresponding to full length EN2 protein (33kDa ; Fig 3) , but not after prostatectomy in the same patients and not in non-cancer individuals.
The ELISA assay for EN2 (supplemental Fig 2) was used to screen representative populations of patients with prostate cancer and relevant controls. The stability of EN2 protein in urine was shown to be at least four days at room temperature (supplemental Fig 3) , allowing postal collection of some samples. The demographics of patients and control groups are shown in table 1. The mean age of men in the study was similar (range 57-67 years).
Median PSA (6·3-7·6 ng/ml) was similar in men suspected of PC versus the two low PSA control groups (0·9-1·1 ng/ml), as expected. Using a cut off of 42·5μg/L, EN2 protein was detected in 54 of the 82 (66%) men with PC confirmed by biopsy ('Biopsy (+)'). Notably, in 9 men in this EN2 positive group the PSA was < 2.5 ng/ml. In men with high PSA and no cancer on biopsy ('Biopsy (-)'), EN2 was detected in 6 of 58 (10·3%). In our control groups EN2 detection was also infrequent: in 'low PSA group A' EN2 was detected in 2 of 17 (11·7%); in low PSA group B EN2 was detected in 4 of 27 (14·8%). An exceptionally high level of EN2 was found in the urine of one individual in control 'low PSA group B' who had a PSA of 1.2ng/ml.
An ROC analysis for this data (Biopsy (+) v Biopsy (-)) revealed that the area under the curve was 0.8021 (p<0·001), indicating a high diagnostic potential for EN2 (Fig 4b) . The mean concentration of EN2 protein was 10·4 fold higher in PC patients compared to that in all the men that were not known to have cancer (Fig 4a) . We found no significant correlation between EN2 expression and combined Gleason score, although the majority of patients in our cohort had disease with a combined Gleason score of 6 or 7 (Fig 5a) . There was also no significant correlation between serum PSA level and presence or absence of urinary EN2 (Fig 5b) . EN2 was also found in the urine of 3 of 10 men (30%) with high grade prostatic intraepithelial neoplasia (HGPIN; Table 1 ; Fig 4a) ; two of these 3 men were found to have PC within 6 months upon re-biopsy.
In order to validate our findings with respect to urinary EN2 secretion, a similar study was completed independently at Cambridge University following the same collection protocol. EN2 detection by ELISA followed exactly the same protocol as for the Surrey University study. The results are summarised in Table 1 and are similar to those obtained for the Surrey patients. Of 13 control patients two were found to have EN2 in their urine (15%), whilst 47 of 81 patients with prostate cancer were positive for EN2 (58%).
Discussion
In this study we have shown that the transcription factor En2 is expressed by PC-derived cell lines and in primary prostate tumours, but not in normal prostate tissue. Our data indicates that EN2 protein is also secreted by both cell lines and primary tumours, and is found in the majority of PC patients in first pass urine collected without preceding DRE, but not in non-cancer controls. We found that EN2 is associated with a sensitivity of 66% and specificity of almost 90% using the 42·5 ng/ml cut off. The maximum specificity that can be achieved using this assay is 100%, using a cut off at 1927 ng/ml, but the resulting sensitivity is only 2·5%. The maximum sensitivity (73%) is achieved using a cut off at 1·5 ng/ml and the resulting specificity is 80%. The cut off value of 42·5 ng/ml was selected to give both high sensitivity and specificity. ureteric) is currently being determined to address its ultimate specificity for prostate cancer. In addition, a larger multicentre study is planned to determine whether EN2 could be used as a monitoring tool (PSA was originally approved for this purpose), the effect of surgery, hormonal and radiotherapy on EN2 secretion into urine, and also whether levels of urinary EN2 correlate with tumour stage and Gleason grade. However, as with every PC biomarker in development, the ultimate question will be centred around the utility of EN2
(alone or in combination with other markers) in identifying 'significant' cancers that require early intervention. have PC. These are split into two groups, patients whose urine was positive for EN2 (EN2+), and negative for EN2 (EN2-). The horizontal bar represents the mean value for each group; the P value associated with these means is shown. 'Combined' -data for all patients in this group. 
